Glioma is the most common primary malignant tumor in the central nervous system. Disulfidptosis is a recently identified programmed cell death in tumor cells overexpressing SLC7A11 under glucose starvation. Clinical prognostic significance of disulfidptosis has been reported in several tumors, and in this study, we explored the correlation of disulfidptosis with clinical prognosis, immune cell infiltration, and immunotherapy response in glioma. A total of 1592 glioma patients were included in this study, including 691 glioma patients from The Cancer Genomic Atlas (TCGA), 300 patients with from the Chinese Glioma Genomic Atlas (CGGA) array, 325 patients from CGGA sequencing, and 276 patients from Gene Expression Omnibus (GEO) GSE16011. R software (V4.2.2) and several R packages were applied to develop the risk score model and correlation calculation and visualization. Three disulfidptosis-related genes, LRPPRC, RPN1, and GYS1, were screened out and applied to establish the risk score model. Low-risk patients exhibit favorable prognosis, and the disulfidptosis-related signature significantly correlated with clinicopathological properties, molecular subtypes, and immunosuppressive microenvironment of glioma patients. We developed a disulfidptosis-related risk model to predict the prognosis and immune features in glioma patients, and this risk model may be applied as an independent prognostic factor for glioma.

Background: Cirrhosis and other chronic liver diseases are the 12th leading cause of death globally and impose a substantial economic burden. Estimating the macroeconomic burden and distribution can provide a policy rationale for the prevention and treatment of these issues. We aimed to estimate and project the macroeconomic burden of cirrhosis and other chronic liver diseases in 190 countries and territories, as well as their distribution across world regions. Methods: We calculated the macroeconomic burden of cirrhosis and other chronic liver diseases in 190 countries using a health-augmented macroeconomic model that accounts for the impact of morbidity and mortality on labor supply, age differences in education and experience among those affected by cirrhosis and other chronic liver diseases, and reduced investment due to the shifting of costs of these disease-related treatments from savings. Results: Our findings suggest that cirrhosis and other chronic liver diseases will cost the world economy INT$ 2.649 trillion (2.502–2.827) in 2021–2050. The United States has the largest economic burden of cirrhosis and other chronic liver diseases, followed by China and India. Although low- and middle-income countries have the highest health burdens (91.4% of the global disability-adjusted life years), their share of the economic burden of cirrhosis is only 57.1% of the global loss. Conclusions: The macroeconomic burden of cirrhosis and other chronic liver diseases is sizeable and distributed unequally across countries and world regions. Our study emphasizes the need for greater investment globally in controlling cirrhosis and other chronic liver diseases and their associated health and economic burdens.

Interventional therapies and systemic chemotherapy are the mainstay of treatment for patients with unresectable hepatocellular carcinoma (HCC). This study aimed to generate preliminary evidence regarding the feasibility and safety of transarterial chemoembolization (TACE) combined with hepatic artery infusion chemotherapy (HAIC), targeted therapy, and immunotherapy in patients with unresectable hepatocellular carcinoma (HCC). This retrospective study analyzed 213 patients with unresectable HCC treated with TACE plus HAIC, targeted therapy, and immunotherapy (THTI) or HAIC plus targeted therapy and immunotherapy (HTI) between July 2019 and August 2023. Propensity score matching (PSM) was used to balance potential confounders between patients in the THTI and HTI groups. Overall survival (OS) was assessed using Kaplan-Meier analysis, and the log-rank test was used for between-group comparisons. Cox proportional hazards regression models were used to identify independent influences on patient OS. A total of 213 patients were treated with THTI (n = 41) or HTI (n = 172). After 1:2 PSM, there were 31 patients in the THTI and 62 patients in the HTI groups. After PSM, OS was significantly better in the THTI than in the HTI groups (34.4 vs. 16.3 months, P = 0.013). The objective response rate (ORR) (38.71% vs. 45.16%, P = 0.554) and disease control rate (DCR) (80.65% vs. 79.03%, P = 0.856) were not statistically significant in the THTI and HTI groups. THTI treatment is an independent predictor of OS. All adverse events (AEs) in the THTI and HTI groups were manageable. Compared with HTI, THTI was associated with improved OS in patients with unresectable HCC, with manageable short-term AEs. Quadruple therapy showed encouraging antitumor activity in this retrospective cohort and should be considered exploratory, further large-scale prospective studies are required.